Education
About Us
Working with TipRanks
Follow Us
Recursion Pharmaceuticals (RXRX)
NASDAQ:RXRX
Earnings Data
Report Date
Aug 12, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.36Last Year’s EPS
-0.4Same Quarter Last Year
Based on 5 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:May 05, 2025
|% Change Since: -22.98%
|Next Earnings Date:Aug 12, 2025
Earnings Call Sentiment|Neutral
The earnings call reflected a balanced sentiment. While Recursion highlighted strong financials, successful platform evolution, and significant partnerships, they also faced challenges with program discontinuations and limited success in certain trials. The company's focus on pipeline advancements and strategic partnerships suggests a cautiously optimistic outlook.Company Guidance
In the recent earnings call, Chris Gibson, CEO of Recursion, highlighted the company's strategic focus on refining its R&D portfolio and leveraging its Recursion Operating System 2.0. The company is prioritizing over five clinical and preclinical programs, with a particular emphasis on oncology and rare diseases, aiming for first or best-in-class potential. Recursion has successfully brought in more than $450 million through collaborations, including a recent fourth program option from Sanofi. The company aims to validate hypotheses faster, generate candidates with fewer synthesized molecules, and reduce costs while accelerating development. Additionally, the company remains focused on disciplined capital allocation, maintaining a cash runway into mid-2027, with a projected operational budget of $450 million or less for 2025.Strong Financial Position
Recursion ended the quarter with $509 million in cash and expects a cash runway into mid-2027. The company has brought in $450 million from partnerships to date.
Successful Platform Evolution
The evolution from Recursion 0.1 to Recursion 2.0 has enabled the company to validate hypotheses more quickly, generate candidates with fewer molecules synthesized, and spend less while moving faster.
Partnership Milestones
Recursion has achieved four milestones with Sanofi and a major milestone with Roche, highlighting strong external validation of their approach.
Pipeline Advancements
The company is advancing over five internally developed programs with first or best-in-class potential, targeting unmet needs with a clear and efficient path to development.
---
RXRX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
RXRX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| May 05, 2025 | $5.70 | $4.76 | -16.49% |
| Feb 28, 2025 | $7.67 | $7.51 | -2.09% |
| Nov 06, 2024 | $6.97 | $6.93 | -0.57% |
| Aug 08, 2024 | $6.37 | $6.64 | +4.24% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Recursion Pharmaceuticals (RXRX) report earnings?
Recursion Pharmaceuticals (RXRX) is schdueled to report earning on Aug 12, 2025, TBA Not Confirmed.
What is Recursion Pharmaceuticals (RXRX) earnings time?
Recursion Pharmaceuticals (RXRX) earnings time is at Aug 12, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is RXRX EPS forecast?
RXRX EPS forecast for the fiscal quarter 2025 (Q2) is -0.36.
---